263 related articles for article (PubMed ID: 32247710)
1. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
[TBL] [Abstract][Full Text] [Related]
6. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
8. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
9. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice.
Martínez-Moragón E; Climent M; Chiner E; Fernández-Aracil C; Sánchez-Toril F; Lluch-Tortajada I
Farm Hosp; 2019 May; 43(3):101-109. PubMed ID: 31072288
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
17. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
18. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.
Tadrous M; Khuu W; Lebovic G; Stanbrook MB; Martins D; Paterson JM; Mamdani MM; Juurlink DN; Gomes T
Ann Allergy Asthma Immunol; 2018 Jan; 120(1):59-65.e2. PubMed ID: 28986124
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
Zhou H; Lu Y; Wu B; Che D
J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
[No Abstract] [Full Text] [Related]
20. Impact of omalizumab on medical cost of childhood asthma in Japan.
Yoshikawa H; Iwata M; Matsuzaki H; Ono R; Murakami Y; Taba N; Honjo S; Motomura C; Odajima H
Pediatr Int; 2016 May; 58(5):425-8. PubMed ID: 27173421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]